linjc16/ctgov huggingface dataset:
Evaluation of Zapperclick Device for Relief From Mosquito Bites

Study Overview
=================
Brief Summary
-----------------
Mosquito bites commonly result in redness, swelling and itching. This study will determine if a device that emits a small piezo-electrical impulse can provide relief from these symptoms. Volunteers entering the study will have a mosquito bite on one forearm. Redness and irritation will be recorded periodically for 24 hours. Comparing data from subjects randomised to the treatment or a placebo device will be analysed to determine effectiveness of the product. We will also ask the subjects their view on how easy the product is to use and clarity of instructions provided.

Official Title
-----------------
Evaluation of a Piezoelectric Device (Zapperclick) for Relief From Mosquito Bites

Conditions
-----------------
Insect Bites, Stings

Intervention / Treatment
-----------------
* Device: Zapperclick
* Device: Inactivated zapperclick device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: known rection to mosquito bites willing to attend clinic for 2 hours during measurements informed written consent Exclusion Criteria: hypersensitivity to bites or stings atopic allergy pacemaker pregnant / breast feeding use of other medication including pain killers

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Use of zapperclick on mosquito bite | Device: Zapperclick<br>* Device deliveres small piezoelectrical discharge to bite site (forearm)<br>|
| Placebo Comparator: 2<br>use of inactivated zapperclick on mosquito bite | Device: Inactivated zapperclick device<br>* placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| reduction in itching |  | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| reduction in erythema / oedema |  | 24 hours |
A Prospective, Observational Trial on the Diagnostic and Prognostic of LM

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to compare the positive rate between the cell-free DNA and cytological examination of cerebrospinal fluid in Advanced lung cancer with leptomeningeal metastases.

Official Title
-----------------
A Prospective, Observational Trial on the Diagnostic and Prognostic Value of Cell-free DNA in Advanced Lung Cancer With Leptomeningeal Metastases

Conditions
-----------------
Lung Neoplasms, Meningeal Carcinomatosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient who was confirmed primary lung cancer by pathologic histology or cytology Adult patients (≥18 years and ≤75 years). ECOG Performance Status 0 or 1.Life expectancy of at least 12 weeks. Clinical symptoms and imaging tests are highly suspicious of advanced lung cancer with leptomeningeal metastases Without contraindications to lumbar puncture Exclusion Criteria: Patients who have primary benign or malignant brain tumor and metastatic malignant brain tumor Patients who have contraindications to lumbar puncture Serious uncontrolled systemic disease including active infection,uncontrolled hypertension,diabetes,unstable angina,congestive heart failure,myocardial infarction,severe arrhythmia which needs drugs,hepatic、renal and metabolic disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| positive rate between the cell-free DNA and cytological examination of cerebrospinal fluid |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The relationship between the number of cell-free DNA and OS |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lung cancer, leptomeningeal metastases, cell-free DNA
The Influence of Genetic Predisposition on Outcome After Catheter Ablation of Atrial Fibrillation.

Study Overview
=================
Brief Summary
-----------------
Catheter ablation is an established standard therapy in interventional treatment of atrial fibrillation.The trial investigates the influence of genetic risk for the recurrence of atrial fibrillation after catheter ablation.

Detailed Description
-----------------
Catheter ablation is an established standard therapy in interventional treatment of atrial fibrillation. electric isolation of the pulmonary veins, from which atrial fibrillation is originating in most patients, is cornerstone of all atrial fibrillation patients. The most common cause for AF recurrence is still incomplete isolation of the pulmonary veins, on the other hand, only 80% of paroxysmal and 60 % of persistent patients can successfully be cured from atrial fibrillation (despite of isolated pulmonary veins after multiple ablation procedures). By now, non-procedure related predictive risk factors, resulting in recurrence of atrial fibrillation after catheter ablation, are only partially identified, such as obesity, hypertension and sleep apnea. In the past year several genetic risk alleles were identified, which are associated with atrial fibrillation. By now the relation between genetic risk, which is determined for every patient by its specific genotype and the outcome of catheter ablation in paroxysmal and persistent atrial fibrillation has not yet been investigated. The aim is to investigate the influence of genetic risk for the recurrence of atrial fibrillation after catheter ablation.

Official Title
-----------------
Untersuchung Des Einflusses Von Genetischem Risiko Auf Den Erfolg Einer Katheterablation Bei Paroxysmalem Und Persistierendem Vorhofflimmern

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients planned for primary ablation due to paroxysmale or persistent atrial fibrillation written informed consent Exclusion Criteria: patients under 18 years of age or patients not able to give informed consent prior left atrial ablation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: no intervention|this is not an interventional study|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Influence of genetic risk on atrial fibrillation | Analysation of the influence of genetic risk on the probability of recurrence of atrial fibrillation after catheter ablation | 10ml blood sample taken at baseline visit (routine blood sample) |
Proximal Hamstring Avulsion Surgery Cohort Study

Study Overview
=================
Brief Summary
-----------------
Proximal hamstring rupture is a rare injury, which may be immediately diagnosed. In 1996, Sallay showed that functional results of surgical repair were better than those of conservative treatment. Surgery is now the rule. The main aim of this study is to obtain a more detailed and quantified description of the postoperative outcomes.

Conditions
-----------------
Proximal Hamstring Rupture

Intervention / Treatment
-----------------
* Other: Proximal hamstring tendons repair


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: a partial or complete hamstring proximal rupture, treated surgically diagnosis of rupture based on clinical signs and confirmed on MRI Exclusion Criteria: no exclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Proximal hamstring tendons repair|Proximal hamstring tendons repair|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Activity level | UCLA (University of California, Los Angeles ) score | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Return to sports | Yes/no | 1 year | 
| Healing on MRI |  | 6 months |
Distant Healing for HIV/AIDS

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether individuals praying at a distance (also known as Distant Healing) can positively affect the health of people with HIV/AIDS.

Detailed Description
-----------------
Significant numbers of people with HIV/AIDS seek spiritual or psychic treatment. Distant healing could potentially be of benefit to large numbers of HIV/AIDS patients, as it is widely available and requires no travel or other activity on the part of the patient. However, the treatment can be costly and has not yet been proven effective in a controlled clinical trial. This study will evaluate the efficacy of distant healing in patients with HIV/AIDS. Participants in this study will be randomly assigned to either the distant healing group or a control group. All participants will have hour-long study visits at entry and Months 6 and 12. At study visits, participants will complete a demographic questionnaire, self-report health and symptom inventory, quality of life assessment, and profile of mood states. Blood will be drawn at each study visit.

Official Title
-----------------
Distant Healing Efforts for AIDS by Nurses and Healers

Conditions
-----------------
HIV Infections, AIDS

Intervention / Treatment
-----------------
* Behavioral: Non-local/distant healing or prayer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria HIV infection History of a CD4 cell count less than 200 cells/mm3 Stable antiretroviral regimen English-speaking Exclusion criteria Inability or unwillingness to fill out questionnaires History of non-HIV related life-threatening disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Non-local/distant healing or prayer|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AIDS, HIV, Prayer, Healing, Complementary Therapies
Bowel Preparation for Inpatient Colonoscopy

Study Overview
=================
Brief Summary
-----------------
This study will compare two strategies for bowel cleansing prior to inpatient colonoscopy: the entire preparation taken the night before the procedure versus half the preparation taken the night before the procedure, and the other half taken the morning of the procedure.

Official Title
-----------------
Single Blind, Randomized, Controlled Trial of Conventional Versus Split-Dose Bowel Preparation for Inpatient Colonoscopy

Conditions
-----------------
Gastrointestinal Hemorrhage, Colon Cancer, Diverticulosis

Intervention / Treatment
-----------------
* Drug: Go-Lytely
* Drug: Go Lytely


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: any diagnosis for which colonoscopy is indicated Exclusion Criteria: ileus severe colitis/toxic megacolon gastric retention bowel perforation gastrointestinal obstruction gastroparesis that precludes oral bowel preparation pregnant or lactating women allergy to polyethylene glycol. unable to give consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Split prep<br> | Drug: Go Lytely<br>* Bowel cleansing agent<br>|
| Active Comparator: Whole prep<br> | Drug: Go-Lytely<br>* Bowel cleansing agent<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of colon cleansing |  | 24 hours from study enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient satisfaction |  | 24 hours from study enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colonoscopy, Bowel preparation
An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG

Study Overview
=================
Brief Summary
-----------------
Children with growth failure due to inadequate secretion of growth hormone or growth retardation due to Turner's syndrome are individually dosed and treated for 12 weeks

Detailed Description
-----------------
Ferring Pharmaceuticals A/S has developed a new ZOMACTON 10 mg formulation. The formulation provides a higher concentration and thereby a smaller volume to be administered. ZomaJet Vision X is a needle-free injection system. It sends a thin jet of ZOMACTON through the skin and into the subcutaneous tissue without the use of a needle. The mode of administration is referred to as transjection. By use of ZomaJet Vision X, both transjection and reconstitution of ZOMACTON 10 mg can be done without using a needle. The rationale of the study is to describe the local tolerability of the new ZOMACTON 10 mg administered by ZomaJet Vision X.

Official Title
-----------------
An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG (Recombinant Somatropin) Administered by ZomaJet Vision X

Conditions
-----------------
Turner's Syndrome

Intervention / Treatment
-----------------
* Drug: ZOMACTON


Participation Criteria
=================
Eligibility Criteria
-----------------
Subjects between the ages of 3 and 17 years (both inclusive) with growth failure due to inadequate secretion of growth hormone or growth retardation due to Turner's syndrome. Subjects have for a minimum of 6 months prior to study enrolment been receiving growth hormone therapy

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: ZOMACTON|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the local tolerability of an individualised dose of ZOMACTON 10 mg administered by ZomaJet Vision X |  |  |
Short-term Effects of Oxytocin Nasal Spray on Chronic Tinnitus

Study Overview
=================
Brief Summary
-----------------
The study compares the short-term tinnitus reduction following a single oxytocin intervention with a placebo control condition.

Official Title
-----------------
Short-term Effects of Oxytocin Nasal Spray on Chronic Tinnitus

Conditions
-----------------
Chronic Tinnitus

Intervention / Treatment
-----------------
* Drug: Syntocinon
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: chronic tinnitus with a duration > 6 months medical examination by an ENT specialist sufficient knowledge of the Portuguese language to follow the instructions and answer the questionnaires VAS score >4 points Exclusion Criteria: vascular tinnitus muscular tinnitus conductive hearing loss previous experience with oxytocin nasal spray additional medications during the intervention

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Oxy-Placebo<br>Syntocinon first, Placebo second 2 puffs in each nostril | Drug: Syntocinon<br>* Oxytocin nasal spray<br>* Other names: Oxytocin;Drug: Placebo<br>* distilled water in nasal spray<br>* Other names: distilled water;|
| Other: Placebo-Oxy<br>Placebo first, Syntocinon second 2 puffs in each nostril | Drug: Syntocinon<br>* Oxytocin nasal spray<br>* Other names: Oxytocin;Drug: Placebo<br>* distilled water in nasal spray<br>* Other names: distilled water;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of tinnitus on VAS |  | 30 minutes after intervention | 
| Change of Clinical global impression scale |  | 30 minutes after intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Audiometry measured in dB HL | measured in dB HL | within one hour before intervention | 
| Minimum Masking Level measured in dB HL | measured in dB HL | within one hour before intervention | 
| Tinnitus Matching | Frequency measured in Hz | within one hour before intervention |
Comparison of Proton Pump Inhibitor and H2 Receptor Blocker on Prevention of Bleeding From Iatrogenic Ulcer After Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Controlled Trial

Study Overview
=================
Brief Summary
-----------------
after endoscopic submucosal dissection(ESD) of early gastric cancer, conventional proton pump(PPI) inhibitors and H2 receptor antagonists have a controversial effect on preventing bleeding from artificial ulcers. the aim of this study was to investigate whether a stronger acid suppression (high dose PPI) more effectively prevents bleeding after ESD

Official Title
-----------------
Comparison of Proton Pump Inhibitor and H2 Receptor Blocker on Prevention of Bleeding From Iatrogenic Ulcer After Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Controlled Trial

Conditions
-----------------
Delayed Bleeding

Intervention / Treatment
-----------------
* Drug: high dose proton pump inhibitor
* Drug: H2RB


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: the patients who agreed informed consent gastric adenoma or early gastric cancer which is eligible for conventional ESD indication Exclusion Criteria: recent drug history of PPI, H2 rector antagonist, bismuth and antibiotics within 4 weeks recent drug history of anticoagulant or antiplatelet agent within 7 days s/p subtotal gastrectomy recurred gastric adenoma or cancer pregnant or breast feeding patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: high dose proton pump inhibitor<br> | Drug: high dose proton pump inhibitor<br>* IV loading PPI before 2hr to conduct ESD, and IV 8mg/h continuous infusion within 48hr, and then 40mg oral pantoprazole for one month<br>* Other names: pantoprazole;|
| Active Comparator: H2 receptor antagonist<br> | Drug: H2RB<br>* IV 50mg loading H2 receptor antagonist before 2hr to conduct ESD, and IV 13mg/h continuous infusion within 48hr, and then 300mg oral H2 receptor antagonist for one month<br>* Other names: curan;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bleeding incidence after ESD |  | time to occur delayed bleeding within one month after ESD | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the size of healing ulcer after ESD |  | follow up endoscopy for the healing of iatrogenic ulcer after one month ESD |